-
1.发明申请MEANS AMD METHODS APPLYING sFlt-1/PIGF OR ENDOGLIN/PIGF RATIO TO RULE OUT ONSET OF PREECLAMPSIA WITHIN A CERTAIN TIME PERIOD 审中-公开意味着在某些时间段内应用sFlt-1 / PIGF或EndogLIN / PIGF比例的AMD方法可以排除前列腺素公开(公告)号：US20150338415A1
公开(公告)日：2015-11-26
申请号：US14576944
申请日：2014-12-19
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Martin Hund , Maria Schoedl
CPC classification number: G01N33/689 , G01N2333/475 , G01N2333/515 , G01N2333/71 , G01N2333/912 , G01N2800/368 , G16H50/30 , G16H50/70
Abstract: The present invention concerns the field of diagnostic assays for prenatal diagnosis of preeclampsia. In particular, it relates to a method for diagnosing whether a pregnant subject is not at risk for preeclampsia within a short window of time comprising a) determining the amount of at least one angiogenesis biomarker selected from the group consisting of sFlt-1, Endoglin and PlGF in a sample of said subject, and b) comparing the amount with a reference, whereby a subject being not at risk for developing preeclampsia within a short period of time is diagnosed if the amount is identical or decreased compared to the reference in the cases of sFlt-1 and Endoglin and identical or increased in the case of PlGF, wherein said reference allows for making the diagnosis with a negative predictive value of at least about 98%. Further contemplates are devices and kits for carrying out said method.
Abstract translation: 本发明涉及先兆子痫产前诊断的诊断测定领域。 特别地，本发明涉及一种用于诊断怀孕受试者在短时间内是否不存在先兆子痫风险的方法，其包括：a）确定选自下组的至少一种血管发生生物标志物的量：sFlt-1，Endoglin和 所述受试者的样本中的PlGF，以及b）将所述量与参考文献进行比较，由此诊断在短时间内不处于发生先兆子痫风险的受试者，如果与所述受试者的参考相比，所述量相同或减少 的sFlt-1和Endoglin，并且在PlGF的情况下相同或增加，其中所述参考文献允许以至少约98％的阴性预测值进行诊断。 进一步考虑的是用于执行所述方法的装置和套件。
-
公开(公告)号：US20250116675A1
公开(公告)日：2025-04-10
申请号：US18798760
申请日：2024-08-08
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Martin Hund , Maria Schoedl
Abstract: The present invention concerns the field of diagnostic assays for prenatal diagnosis of preeclampsia. In particular, it relates to a method for diagnosing whether a pregnant subject is not at risk for preeclampsia within a short window of time comprising a) determining the amount of at least one angiogenesis biomarker selected from the group consisting of sFlt-1, Endoglin and PlGF in a sample of said subject, and b) comparing the amount with a reference, whereby a subject being not at risk for developing preeclampsia within a short period of time is diagnosed if the amount is identical or decreased compared to the reference in the cases of sFlt-1 and Endoglin and identical or increased in the case of PlGF, wherein said reference allows for making the diagnosis with a negative predictive value of at least about 98%. Further contemplates are devices and kits for carrying out said method.
-
公开(公告)号：US12085573B2
公开(公告)日：2024-09-10
申请号：US14576944
申请日：2014-12-19
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Martin Hund , Maria Schoedl
CPC classification number: G01N33/689 , G16H50/30 , G16H50/70 , G01N2333/475 , G01N2333/515 , G01N2333/71 , G01N2333/912 , G01N2800/368
Abstract: The present invention concerns the field of diagnostic assays for prenatal diagnosis of preeclampsia. In particular, it relates to a method for diagnosing whether a pregnant subject is not at risk for preeclampsia within a short window of time comprising a) determining the amount of at least one angiogenesis biomarker selected from the group consisting of sFlt-1, Endoglin and PlGF in a sample of said subject, and b) comparing the amount with a reference, whereby a subject being not at risk for developing preeclampsia within a short period of time is diagnosed if the amount is identical or decreased compared to the reference in the cases of sFlt-1 and Endoglin and identical or increased in the case of PlGF, wherein said reference allows for making the diagnosis with a negative predictive value of at least about 98%. Further contemplates are devices and kits for carrying out said method.
-
-
Search Results
3
records
(took 0.016 seconds)
